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During the 2009 influenza pandemic, a monovalent 
AS03-adjuvanted vaccine was almost exclusively used 
in Germany for immunisation against the 2009 pan-
demic influenza A(H1N1) virus. One-dose vaccination 
was recommended for all age groups. We applied the 
screening method for the rapid assessment of vaccine 
effectiveness (VE) based on reported data of vacci-
nated and unvaccinated pandemic influenza cases and 
vaccination coverage estimates. Preliminary results 
demonstrate excellent VE in persons aged 14-59 years 
(96.8%; 95% confidence interval (CI): 95.2-97.9) and 
moderately high VE in those 60 years or older (83.3%; 
95% CI: 71.0-90.5). 
Introduction
In Germany, vaccination against pandemic influenza 
A(H1N1) 2009 was initiated on 26 October (calendar 
week 44) with the monovalent AS03-adjuvanted H1N1-
vaccine Pandemrix® containing 3,25 µg haemagglu-
tinin. At the onset of the vaccination campaign, the 
number of reported pandemic influenza cases had just 
begun to rise rapidly and eventually peaked in week 47 
(Figure 1). 
A non-adjuvanted vaccine was introduced seven 
weeks later but was restricted to pregnant women. In 
a randomised clinical trial a higher dose of the AS03-
adjuvanted vaccine (5.25 µg haemagglutinin) showed 
seroconversion and seroprotection rates over 96% 
after one shot [1]. Based on these data, the German 
regulatory authority recommended that one dose was 
sufficient for immunisation against 2009 pandemic 
influenza A(H1N1). While immunogenicity data remain 
the basis for licensure of these vaccines, it is unknown 
how well they correlate with protection [2]. Therefore, 
it is essential to estimate vaccine effectiveness (VE) 
from post-marketing surveillance data to confirm that 
the one-dose vaccination regimen induces sufficient 
protection in different age and risk groups [3]. Here 
we present results from the analysis of breakthrough 
infections reported through the statutory disease noti-
fication system in Germany and report VE estimated 
using the screening method [4,5]. 
Methods
With onset of the pandemic, influenza surveillance 
in Germany was intensified. Notified 2009 pandemic 
influenza A(H1N1) cases were interviewed by local 
public health officials for underlying chronic diseases, 
hospitalisation, and influenza vaccination status. Data 
from studies on seasonal influenza vaccines showed 
that protective antibodies are present in over 90% of 
persons 14 days after vaccination [6]. Therefore we 
defined vaccine failure as laboratory-confirmed pan-
demic influenza in a person vaccinated more than 14 
days prior to illness onset. Potential risk factors for 
vaccine failure were assessed by comparing vaccine 
failure cases with persons vaccinated during the seven 
days prior to disease onset. The latter group was con-
sidered as representative of vaccinated persons in gen-
eral and, assuming reasonably high VE it should have 
included only a small proportion of individuals who 
would have shown true vaccine failure had the infec-
tion occurred at a later point in time. For multivariate 
analysis, logistic regression models were applied using 
stepwise backward removal with inclusion of age, sex, 
and all variables with a p-value of ≤0.2 in univariate 
analysis in the first step. 
To monitor pandemic influenza vaccine uptake in 
Germany, a computer-assisted telephone survey was 
carried out during the vaccination campaign starting 
in calendar week 47. A randomly selected representa-
tive sample of 1,000 individuals of 14 years or older 
was interviewed at two week intervals. Demographic 
information, influenza vaccination status (receipt of 
2009-10 seasonal influenza vaccine or 2009 pandemic 
influenza vaccine, including month of vaccination), as 
well as knowledge of and attitude towards pandemic 
influenza vaccination were elicited using a standard-
ised questionnaire. Average vaccination coverage and 
95% confidence interval (CI) were weighted for repre-
sentativeness of the target population. We estimated 
VE by using the following formula: 
VE = (PPV-PCV) / PPV(1-PCV) x 100%
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where PPV is the proportion vaccinated in the popula-
tion and PCV the proportion of vaccinated cases [4]. 
Laboratory-confirmed pandemic influenza cases noti-
fied in all German federal states from week 47 in 2009 
(the week when first vaccination coverage data were 
available, i.e. three weeks after initiation of the vacci-
nation campaign) to week four in 2010 were included 
in the analysis. Since the exact date of vaccination and 
symptom onset were not available for all vaccinated 
cases, an expansion factor was calculated by dividing 
the total number of cases vaccinated against pandemic 
influenza by the number of vaccinated cases with avail-
able information (Table). 
Results
From week 47 in 2009 to week four in 2010, a total 
of 71,315 laboratory-confirmed pandemic influenza 
cases were notified. Of 45,733 cases with information 
available, 425 (0.93%) were reported to be vaccinated 
against pandemic influenza. Figure 2 shows the distri-
bution of vaccinated cases by number of days between 
date of vaccination and disease onset: 180 were vac-
cinated seven days or less, 48 cases 8-14 days, and 
61 cases more than 14 days prior to disease onset (136 
cases with missing data on vaccination date or symp-
tom onset). 
In univariate analysis, age (proportion of cases 60 
years or older: 11.4% among vaccine failures versus 
3.6% among cases vaccinated seven days or less prior 
Figure 1
Number of reported pandemic influenza cases by calendar week, Germany, week 42, 2009 - week 4, 2010 
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to symptom onset, p=0.027) and previous seasonal 
influenza vaccination (61.8% versus 41.0%, p=0.008) 
were associated with 2009 pandemic influenza vac-
cine failure. Underlying chronic disease (40.0% ver-
sus 28.1%, p=0.093) and hospitalisation (9.8% vs. 
12.7%, p=0.53) were not significantly associated with 
vaccine failure. In multivariate logistic regression only 
age remained independently associated with vac-
cine failure (odds ratio (OR)= 1.82; 95% CI 1.03-3.21). 
Immunosuppression was reported for two (3.3%) cases 
in the vaccine failure group and five (3.0%) in the 
control group. None of the vaccine failure cases were 
pregnant. 
The vaccination coverage assessment included a total 
of 6,009 household interviews and revealed an aver-
age pandemic influenza vaccination coverage of 6.8% 
(95% CI 5.0-9.2) for Germany in persons 14 years and 
older. VE was estimated at 96.8% (95% CI 95.2-97.9) 
for all persons aged 14-59 years and at 83.3% (95% CI 
71.0-90.5) for persons 60 years or older (Table).
Conclusions 
A comparison of the prevalence of potential risk fac-
tors for vaccine failure in the group of cases vaccinated 
in the seven days before disease onset (proxy for suc-
cessfully vaccinated persons) with that in the group 
of vaccine failure cases revealed only older age to be 
significantly associated with vaccine failure, in keep-
ing with the findings from the screening analysis. A 
Cochrane review has shown high VE of seasonal influ-
enza vaccines up to 80% against laboratory-confirmed 
seasonal influenza in healthy adults aged 16 to 65 
years in seasons in which the vaccine matched circulat-
ing strains [7]. In contrast, reviews on the effectiveness 
of seasonal influenza vaccination in the elderly have 
shown low or uncertain effectiveness [8, 9]. These 
reviews identified a lack of high quality, unbiased 
studies using the specific end-point of laboratory-con-
firmed influenza. A few studies on the effectiveness of 
adjuvanted seasonal influenza vaccine were included 
in the Cochrane review on VE in the elderly [8] and all 
used non-specific end-points such as preventing influ-
enza-like illness (ILI), hospitalisation, or emergency 
admissions for pneumonia. However, use of adjuvan-
ted vaccines seems to be a promising approach lead-
ing to improved immune responses compared with the 
conventional vaccines [10]. While lower than in younger 
adults, our results also suggest an acceptable effec-
tiveness of the AS03-adjuvanted pandemic influenza 
vaccine in preventing laboratory-confirmed pandemic 
influenza in the elderly, which should be confirmed in 
further analytical studies.
A statistically significant association of vaccine failure 
with underlying chronic disease was not found, sug-
gesting that on the whole, the vaccine is effective in 
chronically ill persons. However, as this group is rather 
inhomogeneous, an association of vaccine failure with 
Figure 2
Time from pandemic influenza vaccination to date of symptom onset in 298 reported  cases with laboratory-confirmed 
2009 pandemic influenza A(H1N1) and information on exact date of vaccination and symptom onset, Germany , calendar 
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certain diagnoses or therapies cannot entirely be ruled 
out. 
The screening method is a quick and simple tool to 
assess VE in a population with known vaccination 
coverage. With reasonably accurate estimates of vac-
cination coverage, this technique can provide a rough 
guide as to whether further evaluation is necessary [5]. 
Strengths of our study were the statutory notification 
of infections with the 2009 pandemic influenza A(H1N1) 
virus in Germany, the occurrence of more than 70,000 
laboratory-confirmed pandemic influenza cases after 
the implementation of the vaccination campaign, and 
the availability of only one vaccine type against pan-
demic influenza. However, it is possible that vacci-
nated patients with ILI might have been less frequently 
tested for pandemic influenza compared with unvacci-
nated persons, thereby potentially leading to VE over-
estimation. Thus, our results must be regarded as an 
upper-limit estimate. They nevertheless suggest excel-
lent VE of the AS03-adjuvanted pandemic vaccine after 
one dose with lower but still acceptable VE in elderly 
persons.
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